Endpoints
adverse drug reactions, albuminuria
SECONDARY, ADVERSE DRUG REACTIONS
The primary endpoint of the protocol is the percentage change in FF after 4 weeks of treatment in the canagliflozin and control groups. The secondary endpoints are (1) the change in FF, percentage change, and change in (2) mGFR, (3) eRPF, (4) eRBF, and (5) RVR after 4 weeks of treatment; (6) changes in eGFR, HbA1c, and albuminuria after 4 and 12 weeks of treatment; and (7) trend of blood pressure and body weight after 4 and 12 weeks of treatment in the canagliflozin and control groups. In addition, we plan to (8) compare the changes in urinary angiotensinogen levels between the canagliflozin and control groups after 4 weeks of treatment. Moreover, the rate of adverse drug reactions will be assessed for safety.